Changes for EC's Lacerda within Georgette Lalis' medtech-strengthened directorate
This article was originally published in Clinica
The European Commission's Antonio Lacerda has begun working under a different unit managed by Georgette Lalis within Directorate F of the Directorate General Enterprise and Industry.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.